- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536012
Gamification-Augmented Home-Based Exercise for Peripheral Artery Disease (GAMEPAD)
Gamification-Augmented Home-Based Exercise for Peripheral Artery Disease (GAMEPAD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Samantha Coratti
- Phone Number: 215-349-8482
- Email: Samantha.Coratti@Pennmedicine.upenn.edu
Study Contact Backup
- Name: Alexander Fanaroff, MD, MHS
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years of age
- Peripheral artery disease, defined as ankle-brachial index < 0.90, lower extremity CT scan or ultrasound consistent with PAD, angiography with ≥ 70% stenosis in any lower extremity artery, or a history of medical or surgical revascularization
- Owns a smartphone or tablet operating the iOS or Android operating system
Exclusion Criteria:
- Unable or unwilling to provide informed consent, including but not limited to cognitive or language barriers (reading or comprehension)
- Critical limb ischemia, defined as rest pain, ulceration, or tissue loss involving the lower extremity
- Planned lower extremity revascularization
- Prior above or below the knee amputation
- Require a wheelchair or the use of a walking aid other than a cane
- Currently participating in a supervised exercise program for patients with PAD
- Anticipated life expectancy less than 6 months
- Any other reason why it is not feasible to complete the entire 6-month study
- Step count > 7500/day during the baseline data collection period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Via the Way to Health platform, all patients will receive daily text messages that inform them of their previous day's step count for 24 weeks.
|
|
Experimental: Intervention
Participants have a 4-week ramp-up towards their step goal and are asked to maintain the goal for the rest of the study. They receive daily texts informing them if they met their step goal and biweekly texts to encourage walking for exercise. Participants are entered into a game. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level. Participants start in the middle of 5 levels. Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. Every 8 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level. In the follow-up period, participants continue to get a daily text stating if they met their step goal. |
Participants in the intervention arm will receive gamification and social incentives as part of the intervention.
See arm descriptions for more detail.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in daily step count
Time Frame: 16 Weeks
|
Change in daily step count from baseline to the intervention period
|
16 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in daily step count
Time Frame: 24 Weeks
|
Change in daily step count from baseline to the follow-up period
|
24 Weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in daily number of minutes engaged in light, moderate, or vigorous physical activity
Time Frame: 24 Weeks
|
Change in daily number of minutes engaged in light, moderate, or vigorous physical activity from baseline to the intervention period, and from baseline to the follow-up period
|
24 Weeks
|
Change in Walking Impairment Questionnaire score
Time Frame: 24 Weeks
|
Change in Walking Impairment Questionnaire score from baseline to the end of the intervention period, and from baseline to the end of the follow-up period.
Participants are asked to rate the degree of difficulty of various physical activities, ranging from 0 (unable) to 4 (no difficulty).
Scores are divided by the maximum number of points and presented on a scale of 0%-100% where 0% indicates they are unable to do the activity and 100% indicates they have no difficulty.
|
24 Weeks
|
Change in PROMIS mobility, pain interference, and satisfaction with social roles and activities scores
Time Frame: 24 Weeks
|
Change in PROMIS (Patient-Reported Outcomes Measurement Information System) mobility, pain interference, and satisfaction with social roles and activities scores from baseline to the end of the intervention period, and from baseline to the end of the follow-up period.
In the mobility survey, participants are asked to rate the level of difficulty of various physical activities on a scale from 1 to 5, where 1 means they are unable to do the activity and 5 means they have no difficulty.
In the pain interference survey, they are asked to rate the degree to which pain interfered with various activities on a scale from 1 to 5, where 1 indicates pain did not interfere and 5 indicates pain very much interfered.
For the satisfaction with social roles, participants are asked to rate how satisfied they are with their ability to perform various activities on a scale of 1-5, where 1 indicates they are not satisfied and 5 indicates they are very satisfied.
|
24 Weeks
|
Change in SF-36 physical functioning scale
Time Frame: 24 Weeks
|
Change in SF-36 (36-Item Short Form Survey) physical functioning scale from baseline to the end of the intervention period, and from baseline to the end of the follow-up period.
Participants are asked to self-report their health using 8 variously scaled scores.
The scales are re-coded to values from 0 to 100, with 0 indicating lowest functioning/well-being and 100 indicating the highest.
|
24 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander Fanaroff, MD, MHS, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 835034
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterSociety for Vascular SurgeryCompletedPeripheral Artery Disease (PAD)United States
Clinical Trials on Gamification and Social Incentives
-
University of PennsylvaniaCompleted
-
Abramson Cancer Center at Penn MedicineNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingPhysical ActivityUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)WithdrawnCardiovascular DiseasesUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)Enrolling by invitationHeart Failure | Hypertension | Diabetes | Mobility Limitation | Ambulatory DifficultyUnited States
-
University of PennsylvaniaCompleted
-
The University of Hong KongUniversity Grants Committee, Hong KongRecruitingDiabetes Mellitus, Type 2Hong Kong
-
Abramson Cancer Center at Penn MedicineAmerican Heart Association; City of Hope National Medical CenterRecruitingCardiovascular Diseases | Breast Cancer | Prostate Cancer | Physical InactivityUnited States
-
The University of Hong KongUniversity Grants Committee, Hong KongCompletedDiabetes Mellitus, Type 2Hong Kong
-
VA Office of Research and DevelopmentCompletedPhysical ActivityUnited States
-
University of PennsylvaniaProgressive Auto InsuranceCompletedDriving Impaired | Distracted DrivingUnited States